Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's BD Exec Spotlights Neuroscience Pipeline

Executive Summary

Thomas Zioncheck, business development executive at Genentech, outlines the company's upcoming R&D goals and early-stage partnering approach outside of oncology. He highlights Genentech's multiple sclerosis portfolio and adds color to its R&D strategy for products targeting Alzheimer's disease and other neurological conditions.

You may also be interested in...



Genentech's Early Cancer Technology Scout On Partnering, Roche Setup & BD Challenges

There is still much more to be learnt about cancer immunology, particularly what drives cancer cell growth, proliferation and resistance mechanisms, says Kevin Sin, Genentech's VP of oncology business development. Speaking to Scrip at the recent BIO-Europe Spring partnering conference, Sin describes Genentech's partnering strategy in oncology and how, almost a decade after the merger, Roche and Genentech are still working collaboratively and competitively to find the best new science in cancer.

Nurturing The Next Generation Of Top Talent

Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative. 

What Does AI Excellence Look Like In Big Pharma?

Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel